Abstract
This article reviews information on the role of genetic variability in the development, progression, and treatment of heart failure. It focuses primarily on genetic variation in neurohormonal systems, where adrenergic receptors and the renin-angiotensin-aldosterone system are the two most explored areas. The article also reviews the endothelin system and natriuretic peptides. Clinical trial design issues are examined, and suggestions for pharmacogenomic clinical trials are presented. Finally, lessons from the oncology field and the changing regulatory landscape are discussed.
MeSH terms
-
Antihypertensive Agents / therapeutic use
-
Atrial Natriuretic Factor / drug effects
-
Atrial Natriuretic Factor / genetics
-
Cardiotonic Agents / therapeutic use
-
Endothelins / drug effects
-
Endothelins / genetics
-
Heart Failure / drug therapy*
-
Heart Failure / genetics
-
Humans
-
Polymorphism, Genetic
-
Receptors, Adrenergic, alpha / drug effects
-
Receptors, Adrenergic, alpha / genetics
-
Receptors, Adrenergic, beta / drug effects
-
Receptors, Adrenergic, beta / genetics
-
Renin-Angiotensin System / drug effects
-
Renin-Angiotensin System / genetics
Substances
-
Antihypertensive Agents
-
Cardiotonic Agents
-
Endothelins
-
Receptors, Adrenergic, alpha
-
Receptors, Adrenergic, beta
-
Atrial Natriuretic Factor